Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 9, 2014, Pages 1451-1454

  Meunier, Mathieu ^a   Bulabois, Claude Eric ^a   Thiebaut Bertrand, Anne ^a   Itzykson, Raphaël ^b   Carre, Martin ^a   Carras, Sylvain ^a   Garban, Fréderic ^a   Cahn, Jean Yves ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Acute graft versus host disease; Alemtuzumab; Allogeneic hematopoietic cell transplantation; Antibody therapy

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; FEMALE; GRAFT VS HOST DISEASE; HUMAN; MALE; MIDDLE AGED; MORTALITY; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84905578545     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.05.031     Document Type: Article

References (26)

1. Majhail N.S., Rizzo J.D., Lee S.J., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012, 47:337-341.
2. Loiseau P., Busson M., Balere M.L., et al. HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant 2007, 13:965-974.
3. Petersdorf E.W., Longton G.M., Anasetti C., et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995, 86:1606-1613.
4. Bay J.O., Dhedin N., Goerner M., et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005, 80:782-788.
5. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104:1559-1564.
6. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004, 104:649-654.
7. Van Lint M.T., Milone G., Leotta S., et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day+5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006, 107:4177-4181.
8. Ruutu T., van Biezen A., Hertenstein B., et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012, 47:1459-1464.
9. Deeg H.J., Blazar B.R., Bolwell B.J., et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001, 98:2052-2058.
10. Miano M., Cuzzubbo D., Terranova P., et al. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience. Bone Marrow Transplant 2009, 43:423-427.
11. Funke V.A., de Medeiros C.R., Setubal D.C., et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 2006, 37:961-965.
12. Massenkeil G., Rackwitz S., Genvresse I., et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002, 30:899-903.
13. Przepiorka D., Kernan N.A., Ippoliti C., et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000, 95:83-89.
14. Srinivasan R., Chakrabarti S., Walsh T., et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124:777-786.
15. Kernan N.A., Collins N.H., Juliano L., et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986, 68:770-773.
16. Kottaridis P.D., Milligan D.W., Chopra R., et al. Invivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000, 96:2419-2425.
17. Kanda J., Lopez R.D., Rizzieri D.A. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol 2011, 93:586-593.
18. Wandroo F., Auguston B., Cook M., et al. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplant 2004, 34:285-287.
19. Carella A.M., Beltrami G., Scalzulli P.R., et al. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant 2004, 33:131-132.
20. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11(12):945-956.
21. Vigorito A.C., Campregher P.V., Storer B.E., et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009, 114:702-708.
22. Korn E.L. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986, 5:255-260.
23. Schnitzler M., Hasskarl J., Egger M., et al. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009, 15:910-918.
24. Schub N., Gunther A., Schrauder A., et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant 2011, 46:143-147.
25. Jackson K., Curley C., Leach J., et al. Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD. Bone Marrow Transplant 2011, 46:1579-1580.
26. Xhaard A., Rocha V., Bueno B., et al. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant 2012, 18:406-413.